ArticleInternational journal of laboratory hematology2026
Risk Factors of Disseminated Tumor Cells in the Bone Marrow of Patients With Angioimmunoblastic T-Cell Lymphoma and Their Impact on Prognosis.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAngioimmunoblastic T-cell lymphoma (AITL) is a mature T-cell proliferative tumor characterized by an aggressive clinical course and low incidence. The risk factors for the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) of patients and their impact on prognosis remain incompletely understood. In this study, we used multiparametric flow cytometry (MFC) to detect DTCs in the BM of AITL patients. We aimed to assess risk factors for the presence of DTCs, investigate correlations between the immunophenotype of DTCs and clinical indicators or efficacy, and identify prognostic factors. Our findings provide insights that may aid in the early diagnosis, disease monitoring, and efficacy evaluation of AITL.
methodsBased on the presence or absence of DTCs in the BM, 90 patients with an initial diagnosis of AITL were classified into DTCs
resultsMFC detected neoplastic T cells of AITL in 65.56% (59/90) of BM samples. Compared to the DTCs
conclusionThe presence of DTCs in the BM is associated with the prognosis of AITL. Pleural effusion constitutes an independent adverse prognostic factor. Loss of CD7 correlates with shorter OS, and a profile combining CD3 expression, elevated LDH, and decreased HGB serves as a useful predictor of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.